

INDEX

A

Acquired drug resistance176
Activation loop153, 154
Affinity purification143–150
AGC protein kinase134
Allograft221, 223–224, 226
Allosteric
 inhibition140
 inhibitor67–78, 134
 regulation68, 134
 site134, 138, 140, 153
Alpha helical mimetic molecules128
Antagomir185–195
Antibody–carbohydrate interactions42–45
ATP-binding site133–135, 138,
 140, 143, 154
AutoDock3, 4, 7–10, 12–14
Autoinhibition69, 72

B

Bacteriophage phi29198
Bottom-up assembly199

C

Cancer17–19, 29, 40, 53, 70, 81, 161, 162, 175,
 186, 198, 200, 201, 206, 207, 221, 225
Cdc4231, 67, 68, 70–76, 82, 94
Cell-type specific delivery198
Chemicals3, 17–19, 21, 24, 25, 30, 33, 42,
 68, 81–95, 116, 136, 138, 144, 145, 155, 176,
 199–204, 206, 212
Clustering11, 13, 42
Conformational change2, 5–7, 26, 37, 133–141

D

Database search3, 18, 19, 24
DFG-out144, 153, 154, 156
 conformation144, 153, 154
Dimer disruptor120, 121, 128, 130
Dissociation constant21, 39, 46, 156, 158
Docking1–14, 17, 18, 20, 22, 24–26, 31, 32,
 41, 46, 51, 133

Drug

 delivery200
 discovery1, 18, 39

F

Flexible docking2, 6
Fluorescence
 polarization54, 56, 61
 tagged54, 56, 58–59, 170
Fluorescent
 GEF assay99, 101, 116
 probe154–158
Fluorogenic enzyme assay121

G

Ganglioside GD240, 41, 43, 47–51
GTP-binding protein115

H

HHV. *See* Human herpesvirus protease (HHV)
High throughput screening (HTS)18, 54, 59–60,
 120, 121, 124, 162, 170–172
Human herpesvirus protease (HHV)119–121

I

Inactive conformation143–150, 153–159
Inhibitor5, 17–27, 29–37, 53–64, 67–78, 81–95,
 97–117, 119–130, 133, 134, 143–145, 148, 153,
 154, 162, 166, 167, 169, 170, 172, 174, 176, 177
 screening67, 82, 89–90, 97–118

K

Kaposi's sarcoma-associated herpesvirus
 (KSHV)120, 121, 123–126, 128, 129
Kinase67–78, 133–141, 143–150, 153–159,
 163, 166, 173, 175, 176, 181, 183, 224
 inhibitor67, 133, 153, 176
KSHV. *See* Kaposi's sarcoma-associated herpesvirus (KSHV)

M

MDA-MB-231 human breast tumor
 cells (ATCC)222, 224–225

- MicroRNA185–195
Molecular modeling 1, 5, 40–42, 46–47
Murine bone marrow cells.....185–195
- N**
- Nanobiotechnology 197, 200, 202, 203
Nanomotors.....202
¹⁵N HSQC21
Nuclear magnetic resonance (NMR).....1, 17–27, 39–51,
121, 130
structure calculations45, 50
- P**
- Pak kinase..... 68, 71
PCR-based mutagenesis..... 98, 99, 101, 106–107
PDK1 133–141
Peptide
aptamers97–117
inhibitors115
mimetics128
Peptide–carbohydrate interaction41
Peripheral binding site.....55, 56
Polyview-MM 5, 12, 13
pRNA nanoparticle197–216
Protein
conformation 134, 138, 153–159
kinase.....133–141, 143–150, 153–159, 175
ligands 5, 13, 20, 22, 46
structure.....19, 128
tyrosine phosphatases (PTPs).....53–64
PTP inhibitor.....53–64
- R**
- Rational drug design..... 30, 40, 153
Re-ranking 2, 17, 24
Retroviral-screening182
RhoA.....29–36, 82, 94, 98, 101, 113
RhoGEF. *See* Rho guanine nucleotide factor (RhoGEF)
Rho GTPases 29, 30, 81, 82, 94
Rho guanine nucleotide factor (RhoGEF).....30, 80, 82,
98, 101
Rho signaling.....81, 82
- RNA interference (RNAi).....198
RNA nanotechnology.....202
- S**
- SAR. *See* Structure–activity relationship (SAR)
Saturation transfer difference NMR.....39
Screening1–14, 17–27, 30, 32, 33, 54, 56,
59–61, 67–69, 71, 72, 75–76, 82, 88–92, 97–130,
162, 170–172, 175–183
Signaling..... 17–27, 29, 30, 81, 82, 98, 175
Small molecule
docking.....3
inhibitors30, 31, 36, 53, 119–130, 143
Structure.....1, 2, 5–9, 11, 13, 14, 17–26, 30,
39–42, 44–46, 49–51, 55, 56, 120, 122, 128, 140,
144, 153–155, 178, 198–199, 202, 204, 206, 207
Structure–activity relationship (SAR) 18, 25, 153
- T**
- Targeting17–27, 29–37, 40, 55, 67, 98, 101, 120,
133–135, 143, 200, 205, 206
4T1 mouse breast tumor cells.....222
Transferred NOE 40, 48–49
Tumor metastasis..... 40, 221–227
Two-hybrid.....81–94, 98–100, 102–104, 110–112
Tyrosine kinase inhibitors.....176
- V**
- Viral
assembly..... 197, 199, 200
DNA packaging motor.....198
Virtual ligand screening.....17–27
Virtual screening 1–14, 18, 19, 24, 26, 30, 32, 33
Visualization.....1, 5, 6, 11, 13, 150
- X**
- Xenograft..... 206, 224–226
- Y**
- Yeast two-hybrid81–94, 99, 100, 103–104,
110–112